Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 6/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31126834 | 1.00 | KDM4E (0.68) | KDM4EHSD17B10LMNAALDH1A1NPSR1 | |
| SCHEMBL4474267 | 0.92 | CYP1A2 (0.74) | KDM4EHSD17B10LMNAALDH1A1NPSR1 | |
| SCHEMBL11370286 | 0.89 | MEN1 (0.59) | KDM4EHSD17B10LMNAALDH1A1NPSR1 | |
| SCHEMBL27465197 | 0.89 | MEN1 (0.59) | KDM4EHSD17B10LMNAALDH1A1NPSR1 | |
| SCHEMBL3135286 | 0.88 | SMN1; SMN2 (0.82) | KDM4EHSD17B10LMNAALDH1A1NPSR1 | |
| SCHEMBL25833844 | 0.88 | KDM4E (0.62) | KDM4EHSD17B10LMNAALDH1A1NPSR1 | |
| SCHEMBL27506182 | 0.87 | NPC1 (0.58) | KDM4EHSD17B10LMNAALDH1A1NPSR1 | |
| SCHEMBL10501732 | 0.87 | KDM4E (0.78) | KDM4EHSD17B10LMNAALDH1A1NPSR1 | |
| SCHEMBL7312805 | 0.87 | LMNA (0.71) | KDM4EHSD17B10LMNAALDH1A1NPSR1 | |
| SCHEMBL19805148 | 0.87 | MEN1 (0.68) | KDM4EHSD17B10LMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404696-B2 | Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2013-03-26 | — | — | US | claimed |
| EP-2239257-B1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | SHIN POONG PHARMACEUTICAL CO LTD (KR) | 2012-06-06 | — | — | EP | claimed |
| US-20100311769-A1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2010-12-09 | — | — | US | claimed |
| EP-2239257-A2 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | Shin Poong Pharmaceutical Co. Ltd. (KR) | 2010-10-13 | — | — | EP | claimed |
| WO-2023133524-A1 | A PROCESS FOR SYNTHESIZING KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133524-A1 | A PROCESS FOR SYNTHESIZING KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| CN-106866625-B | Preparation method of ketanserin | 上海鼎雅药物化学科技有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-9290480-B2 | Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | Shin Poong Pharmaceuticals Co., Ltd. (KR) | 2016-03-22 | — | — | US | disclosed |
| US-20130102622-A1 | Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2013-04-25 | — | — | US | disclosed |
| US-8404696-B2 | Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2013-03-26 | — | — | US | disclosed |
| EP-2239257-B1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | SHIN POONG PHARMACEUTICAL CO LTD (KR) | 2012-06-06 | — | — | EP | disclosed |
| US-20100311769-A1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2010-12-09 | — | — | US | disclosed |
| EP-2239257-A2 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | Shin Poong Pharmaceutical Co. Ltd. (KR) | 2010-10-13 | — | — | EP | disclosed |
| CN-1793138-B | Process for prepering aspetllinone | BOSU MEDICINE SCI & TECH CO LTD SHANGHAI | 2010-05-12 | — | — | CN | disclosed |
| CN-1793138-A | Process for prepering aspetllinone | BOSU MEDICINE SCI & TECH CO LT (CN) | 2006-06-28 | — | — | CN | disclosed |
| US-5198449-A | N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents | A. H. ROBINS COMPANY INCORPORATED (US) | 1993-03-30 | — | — | US | disclosed |
| US-4952573-A | FOR CONTROLLING TISSUE STABILITY DURING EYE SURGERY; ANTISWELLING AGENT | LABORATOIRS ALCON S.A. (FR) | 1990-08-28 | — | — | US | disclosed |
| US-4711883-A | HYPOTENSIVE AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-12-08 | — | — | US | disclosed |
| EP-0219259-A2 | Substituted 3-(4-phenyl-1-piperazinyl)alkylquinazolin -2,4-(1H,3H)diones, methods of preparation and compositions | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311769-A1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | AQP4, PMP22, CNTN1 | KDM4E 2022/4885HSD17B10 2598/4885LMNA 1933/4885 |
| US-20130102622-A1 | Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same | AQP4, PMP22, CNTN1 | KDM4E 2022/4885HSD17B10 2598/4885LMNA 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.